<SEC-DOCUMENT>0001193125-12-131372.txt : 20120326
<SEC-HEADER>0001193125-12-131372.hdr.sgml : 20120326
<ACCEPTANCE-DATETIME>20120326121623
ACCESSION NUMBER:		0001193125-12-131372
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120326
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120326
DATE AS OF CHANGE:		20120326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		12713867

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d323643d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): March&nbsp;26, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;26, 2012, ARCA biopharma, Inc. announced
results of analyses of atrial fibrillation data from the BEST trial, a previously conducted Phase 3 heart failure trial involving Gencaro (bucindolol hydrochloride), in 2,708 advanced heart failure patients. The press release is furnished as
Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and
Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#146;s Norepinephrine Lowering Likely Contributes To Its Effect In Atrial Fibrillation Prevention,&#148; dated March 26, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March&nbsp;26, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>(Registrant)<B></B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#146;s Norepinephrine Lowering Likely Contributes To Its Effect In Atrial Fibrillation Prevention,&#148; dated March 26, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d323643dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g323643g52v62.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">&#146;S
NOREPINEPHRINE LOWERING LIKELY CONTRIBUTES TO ITS EFFECT IN ATRIAL FIBRILLATION PREVENTION </FONT></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Data Selected for Moderated Poster Presentation at American College of Cardiology
61<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Annual Scientific Session&nbsp;&amp; Expo
</FONT></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gencaro Potentially the First Genetically-Targeted Treatment for </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prevention of Atrial Fibrillation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, March&nbsp;26, 2012</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other
cardiovascular diseases, today announced results of analyses of atrial fibrillation (AF) data from the BEST trial, a previously conducted Phase 3 heart failure (HF) trial involving Gencaro (bucindolol hydrochloride), in 2,708 advanced heart failure
patients. Researchers believe increasing plasma norepinephrine (NE) levels as a measure of adrenergic activity herald worsening of HF in patients with reduced left ventricular ejection fractions (HFREF). In this new analysis, researchers, including
Dr.&nbsp;Michael&nbsp;R. Bristow, ARCA&#146;s CEO, found that patients who developed new onset AF during the BEST trial had higher baseline NE levels than patients who did not develop AF. NE levels at three months decreased in the Gencaro subgroups
compared to placebo subgroups. Researchers believe this sympatholytic effect likely contributed to an associated 41% reduction in the risk of developing AF for the 1,202 Gencaro patient cohort without AF at baseline. As previously reported at the
American Heart Association&#146;s Scientific Sessions 2011, Gencaro reduced the risk of developing AF by 74% in the genetic subgroup that was homozygous for the 389 arginine version of the beta-1 adrenergic receptor, which has high affinity for
norepinephrine. Researchers found that Gencaro&#146;s norepinephrine lowering properties appear to contribute to its effects in all HFREF patients, but in particular those who have only beta-1 389 arginine receptors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The data were selected for moderated poster presentation at the American College of Cardiology 61</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Annual Scientific Sessions&nbsp;&amp; Expo, being held
March&nbsp;24-27, 2012 in Chicago, Illinois. Dr.&nbsp;Ryan Aleong, Assistant Professor of Medicine, Cardiology, Director of Implanted Cardiac Device Clinic, University of Colorado Hospital, and Interim Director of Arrhythmia Services at Denver
Health Medical Center, presented &#147;Bucindolol&#146;s Sympatholytic Properties Contribute to Reduction in the Risk of Developing New Onset Atrial Fibrillation in Patients with Advanced Heart Failure&#148; during the session &#147;Arrhythmias:
AF/SVT: Continuing Role of Pharmacologic Therapy for Atrial Arrhythmias,&#148; Monday, March&nbsp;26, 2012, 11:00am &#150; 12:00pm Central. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Researchers assessed the role of NE in contributing to new onset AF and that of Gencaro in preventing new
onset atrial fibrillation (NAF) in patients with advanced HF in the BEST trial. Baseline NE levels measured by high performance liquid chromatography (HPLC)/electrochemical detection (ECD) were available in 1,868 of the 2,392 enrolled patients who
did not have AF at baseline. New onset AF, which was not a pre-specified endpoint in the BEST trial, was assessed from adverse event (AE)/serious adverse event (SAE) case report forms as well as routinely measured electrocardiograms (ECGs) in
patients not in AF on study entry. In the 2,392 patient cohort without AF at baseline, there were 115/1190 (9.7%)&nbsp;new onset AF episodes in patients in the placebo group, and 75/1202 (6.2%)&nbsp;in the Gencaro group (hazard ratio &plusmn; (95%
confidence intervals) = 0.59 (0.44, 0.79), p =0.0004). Baseline NE was higher among patients with new onset AF compared to patients who did not develop AF (NAF 530&plusmn;281 vs. no AF 498&plusmn;328 pg/ml, p&nbsp;=&nbsp;0.015). NE at three months
decreased in the Gencaro subgroups as compared to placebo subgroups. NE reduction by bucindolol was similar in patients with beta-1 389 arginine/arginine and glycine carrier genotypes, suggesting that the high binding affinity of the 389 arginine
receptor for NE contributes to differential pharmacogenetic efficacy, not differences in NE lowering between genotypes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Atrial
Fibrillation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Atrial fibrillation is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two
small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with atrial fibrillation causes blood to pool in the atria, predisposing the formation of clots. These clots may travel from the heart
and become lodged in the arteries leading to the brain and other organs, thereby blocking necessary blood flow and potentially resulting in stroke. In addition, in patients with heart failure with reduced left ventricular ejection fraction (HFREF),
new onset atrial fibrillation may also contribute to worsening heart failure and increased risk of death. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Studies estimate atrial
fibrillation affected between 2 and 3&nbsp;million Americans in 2005. Those same studies estimate the prevalence of atrial fibrillation will likely increase to between 3.8&nbsp;million and 4.8&nbsp;million by 2025. Industry estimates expect the
atrial fibrillation drug market in developed countries to increase more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019. The Company believes there is an unmet medical need for new atrial fibrillation treatments that have fewer
side effects than currently available therapies and are more effective, particularly in patients with HFREF, where most of the approved atrial fibrillation drugs are contra-indicated or have warnings in their prescribing information. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the
potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more
information please visit <U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, the contribution of Gencaro&#146;s sympatholytic properties to potential reduction of the
risk of developing new onset atrial fibrillation in patients with advanced heart failure, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s
current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and
uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the
Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in
ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these
forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g323643g52v62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g323643g52v62.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0#A`P$1``(1`0,1`?_$`*\```$$`P$!`0``````
M``````@`!@<)`@4*!`$#`0$!``(#`0$!`````````````0<(!`4)!@(#$```
M!@$$`0,#`P(#!`L````!`@,$!08'`!$2""$Q$PDB%!5!42,R%F%Q0O"!4C.1
MH<%B)"4U91<9"A$``0,"!`,%!`@""P```````0`"`Q$$(1(%!C%!!U%A<1,(
M@9$B,J&Q4M(C%"0)T6)"8W.#D],T5&05%O_:``P#`0`"$0,1`#\`[?<U9J;8
MQ:MF$>@A(621(<Z#=8X@@Q;E`H?=.BD'F;F8_P#&3P!^)O/C6D'K!]7]CZ<]
M+@T3;]O%J'46_8YT44A/E6\8H/.G#?B-2?PV"F?*_P"(4QR%L;8\FZ977%RY
MT>EQD`D<7'[+:X>)Y5&"&)KV;RR\-_&6L`03;<AB%_'I_P"X^=@'7GYM3U[^
MKO>-P(]+@VV("?G=I\V7P'ZNI]BRG/TOV;;MK)^:K_:C[B=37/65E0`RAZX/
M[@6&6VW]1W'\B.VMG]O>H7U/WL0DU*70C4_T-/D`Y5&-T:4[UT,^Q=GQFC1<
M^V4?<6Q4SAE1,B9CA7B@LG[B0C$+;&)R,3D'_C_(<BC_`-&OLY^MWJ)AB$CG
MZ.,[*M_1/Q&(K_J.T+B,V9M)SB!^8.4T/X@\?LK2OL_9;:#L']N>``1*>%7`
M=C>2F\2'H("`_P"6L3[P]2OJRT5KGZ7)MUY:T'))I\M>1XB['$<%V5ML+9D_
MS?FJ=TH^XM*S[4Y%CY)`9MC`/6!%0^Z:MF*S)=9+T'V7`O%P3.`#N&Y1`=MA
M\>=8"M/W(O4AM3<D,>_--T2YTAD@\Z&*VEMY'LY^7,;B4!P&(JP@D932M1VD
MW2;;%S;._(R7#)R/A<7AP![VY14>U'33K;$W>O,+'#*"9F^3W%,XE%5LX)L5
MPU5XB)?=;J[D-MX$0\>->SW2;JCMGK'L.QW_`+2>7:5>QU+74SQ2MPEA?3#/
M$_-&XBH):2"0L!:WH]WH6HR:;>C\9AX\G-/RN'<X8A.C61UU26B)B9-R'7L4
M4*TY"M+@&\+589_,.PYD*LZ!DV5<%9-"G$`5>NQ2X)$#R<X@&B*%^J':"M]I
M<?NKA$,`@Y2*F'<--0!W972S-5$B#ALX(?@DHHU<M'28@82A_(!R_P"G1$4>
MB+SNE54&KE=!N=XLBW651:)'334=*IIF.FW345,1(AUS@!0$P@4!'R.VB(!,
MJ=[)+"C<TGDGK'FNOUXKLS,;,`U-]!%."AB$$[YI-J$)[Q2<B`.PF#1$RZ)\
MF=9RO.*U_%&`LT9"D&S?[MX2!:5T2L6X'22%=X9Q+I%;H@HL4.1AVW'16BDB
MY]U+#C9DI-9!ZL9WK=8:D]V3LR;2M343%H^!%5ZI$S#E5,H!O_I_31**8,$=
MK\(=C&Z__P`:VU)Y+LDDU9"M2B*D5861#@/\AHYUQ4<-P,00]U+F3QZAHE$1
M^BB:%WO]+QM`.K1?+-#U6!9E$5Y.9>HLVX#XV33%4P&66,(@`$(!C"(^FB('
MV?R&U._SKJM]?L390S@]:G,DM*P$0G#UQH8H;>^\DY@Z'MM.8@',"CN`@.VV
MBJD-3*_<44/O4.K%<]D3D,#);,=<+)_:BB"RBHI$1,@"P&W("7/GRVT40]WC
MY,'.'9=*#S5ULR?1WS@Q@:K"[A5H]X0#[>\R?.5VK9VD5/ZA$AQ'QX`=%59'
M0KA'9!I-2O40FJE%7"NP]ECDES)F73933!"0;)K&1,=(52)+@!N(B7?T'11.
MW1%^#ITV9-EWCQ=)LU;)'7<.%SE21012*)U%55#B!2)D*`B(B.P!HB#;K/W4
MH/9>XY(J%<9K1;JD/TQBE'BY>5D@UC+H%DFR(E(9-9%TR5!5(.7`G`V_U:(C
M0T1+1$M$59?:4P'S&=$QS`0*S!";8-P`#*2&P>O@3;:\'/7MMAVY_5LRS</T
M_P#Y_3\QQI3S+GC3DMG^E;A'LKS*?%^:EI[F+0U""7?</MH\S\I`#WFR`@94
MB8_ZC\/Y$Q$-]C;#_D.LO]'NF$,=I$ZTMFSQ-`S-8,:<\!BWN-#[5^M<U1L1
M(DDR$\">%?;Q1`L8:KU]H1:8?>W&S3=9M]BL@8LXUD6Y#*-@(T('-5)-90@F
M.4>`AN`CX'6X]AM[9^V+9IU68,L;R,M$1:?S#96`EM(QBX!Q!+AA3`G`K'4]
M[J>HREMHRMQ"X',#^&6$T/Q<B0"*<?>G.QC:S*(P9S-I$48AHLD=11H4$WBA
M%W+MJ4Y2&.)$!55*!]P_IWU]M8Z-MO4H+-YAF\JUB(JY@H\ASGMK0FC<Q%:\
MJU75S76HVTDP#F9Y7`T#OE%`">\T!IWIC6RCF3!15%,\K(.Q.Z!O'D.LS8-S
MF$Q"JK@7914I-@`@>"%VW'<-M8UWMTYA<R26.-UU?S$N#8VDLC8>`+J8D#`-
M&`%,<*+O=)UVM&N(B@905<0'./<.0[SQ^E#':HP6ON)JD*18AO)>9.:9B@(<
M%``PB42C^@[#KSBZ[=++>XLIA)$UMV*D$`$@CD:8@]U%E?1-0\PC*:QGZ>\(
MSNHBAST25*8YC`G+G*`;B)"B*CKEP`?``80\_OK<_P#;/AGM.CFHV,SB1#JL
M@`K4#XY:T'`5.)IQ6'^L(:-?B(%*PCZFHL=>CZQ&EHBJ7[>2,CVRSS5>D]*F
M',?5X-D%]S=9([^9!@1NXW@:VHX1*8S*7`T<X."9_I4]XH"`@&BH58O1'-$S
MU/[@26(,@'5AX>T3H8^LC)XJ8!93"JQBU)T)#A[:0N7,FW,LI].R0^1V#0J5
M[:+J@*8IRE.0Q3D.4#%,40,4Q3!N4Q3!N`E$!W`=$66B*O/Y1W(-.FF3EA$0
M`H07D!V#S/1@>=A#]]%0@/\`A&?D?GSP8-C'2<U(H']1`IVC\1+N.X@`B4!V
M]!T45],RV8O(B3:R2+=Q'KL'2;Q%V1-1LHW,B<%2KD5`4S)\?7<-M$7'YULD
MY=/O#1&6&S/W;1'+3)!F:*45435I_P";;%?&D%0$I?PQTN/OF4XI\=N6G)7C
MPHNN*_WJ#QG1+1D&UK_:P5/K\C89E0G$5"M(MFH\<E1*(@"BQB)"!"@/U#XT
M47+E$WS*7R:]KZ]4;!,NHZF'D'3M&$8.EBPU5ID."CR1.T3-_",S*,4%?;74
M*)S+'*3?B4-$KV474%C+&%(Q!3XFC4"`85^`B&Y$DV[-$I%7:^W\S]^X'DN\
M?.5!$QU%#&-YXAL4"@!$_P#1%$>;L,4O.^/)['UVBF<@SE&2Y8]VN@0[J&E/
M;-]E*,'`D,LV7;K;<A3$HG3$Q!\&'1%Y>ON-)K#V(*1C2>L"-G>TZ&:09)A!
M%5NDY9L$4VS0"H*B)TN"*0!MZ!^FB*9M$5;W?W+,ZNSHW5;&#TY<G]A97^VG
MB[8@K?VW1G9D(R=EI$4CE6CDUB2I127W*!?:.._C154GOW<Y\<?>..1<.'RM
M7@Y"/7%X\.95S8L9SQTVDP^%,@$3.[6%F\(EN&Y3$W]1TK52JZMZW/QMI@(:
MR0[E)W&3D:SE&+A!0BJ:C=X@18FRB8F*(EY\3;#X,`AHBW6B):(JL^UK])MG
M%<B@[;5*OB4=_414DOI'_AW_`$UXM^L6:*W]61=(0,^W[`"O#!]S_'EBMH^E
MD+I-BC+_`+N7ZF+WXR>,7*R1TX:1>G3,0_W",\2.20V\^ZLY,P4*F7</(\R[
M;>NL_P#1VYTVZ;')!9W$LC*?$VX$;6$?:=Y1#0/$475[FAGC:6OFC8#R,9<3
MW`9A7W+V9EG'T7=H>5=KB[A7$8BT8/DWWY9DV717<JK1BDJ4H)'>I%5`YBB.
M_%0O[ZZ#K'NW4MI=7X-3W`7/VU=6K&VEP)/.A:YKWE]MYH&42L!#W-)^61IY
MJ;0L(+S0);6W&6_;*7/9ER.((`#PSCE-*5[0>Q/^LYOB&44+<!;&!1("`8>!
MC#X`/'CEZ_MZZSYMOK?MV/2PP2Q$EO:,%\UJ&R[R2YS4<*'O3W+,*2=-44?M
MU7`O'RCQE#(SQ(5^5@8@I@J,>HDJHY26<`)RAP'<#`/IYU]I_P!L[5MJNGN(
MWR,FE+XX6W`@D,5*9O+(<7`NJ0,M2""%TQM&VVK!L+@,C`UTAC,C<U:TS`@`
M@8''E1!O?I1B@HY238NH\X*"!TG3KWU2<0'<@@#9N/D0]=O'IK0CK/J&FQ1S
MP-BD@E;FP?('$4!%#\#>/L69-MVTS\KR]LC2.(;0>/S%&%TT<%=4&95(`\1F
MC[#ON`_6[]/^[^VM@?VZWM?TSU=S/E.K//O=*L6=96&/7H`>/D#ZFHP=>A2P
M\AS[6]B*SU;P;=,PV4[=3\`Q.E`Q*ZH(GL5E<(K'BH%J<1*7[E^9`_'<0#8H
M^=$51O16_P"?,55Z\98M?3W.V4,E9YL1KA.7^*/4F320K_M@%?CT6\K,MGR?
MV9U7!A$Q"<@4#QXTH51WH!/E(;9#F+_$]C5>N64<!,95JPAK#)VL(,Z$A:V3
MI464VF]@I)^+>060<-4"^YPW]@O$1'3$*$=BZ!_CE[/L.TO66HVI1RDI;ZF4
M*5>6J1B#]K-Q**1V@[`<QS?=02[18QC`&ZBAO\]$1Y:(JSOER>_C^C65W6XE
M!,:]N(?L-ABP_P"W4YHJ>_AV-V.LX9Q5Z_W3%]959&K1)QKDVK3EC:R+A5L\
M/'J,58*6BG+`42)F*<1]P#`;T\:O-`M1W'[U=YJ#DI]@'LQ(LZ'4EGB25E4P
MO#IP:URI3E0R:KNJV6;=2SE-)XW$IP^M%=,#`"@%$>.B55[G1/!W4ND8N@LC
M]9V:%A87.+174R%,N22]Q?)JI)JK1TD[.BA^(72,H'OM$D6_U"',H[%V*\%K
M_D_1G5.E68UH$RA5&$/^1DQ32.L(P;)-=:6`X$$/;3%J4>1Q^DH>1T45(WP6
MVV'=]CLA1CUPV+)O\?M/P:*Q2&<K*-7,JXD09F,43D%)D&ZG$0W)Z^-1%U<Z
MJ):(EHB6B)L72X5_']3L-VM<BWB*Y6(IW,3$DZ,)6[-BS3%1594P`(@4-MO3
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M8^A#26NGS`.I0EM1F`.%17B%MOT7$<VRO*!!>+J6HY@$,I7LK0T\%`=;OHLE
MD2O%%U&J9@W235$BA@#;D4AS%,1+GZ<N/C]AUC[IMU8%E)%::D]X#7"K<U*@
MT!#200#08X'E@OLM5T#SVN,(:)".-/K'/PJBHK^;8Q[&.DK`RBW<(P8G:Q56
M7;)'B5GKHAT2NW"*XJ*.UV`F(M[B@B?<`V$-@VW?T?K%MS<.B36VZK6RNMOQ
M1Y(K*2-CX'R/%`]S'YBY\1+7YR<PH*$4%,5WVS;NWN6OT^25EZ]]7S`D2!HQ
MR@BE`[%M!AVA;AM><7UT:G)-ZG7P7?1SAS/*E:BX]E=R\?L2K-D7!E4VSADW
M*FJD4A2[F*'G<=<NPUWH[M5VEZE8:-IS9YH'/G(!>&ETDD8+&/<YK71M`>P-
M`Q`(Q7&ETC=&HBZMY;NX+&2!L8J!4!K74)%"0XDM))X54>7K,_Y$CF.D%BR2
M30YPAY0AB!(MV9S"=NV54)L5=M[2@;D./),P[`(@`%U\5U`ZX6LL,EG?RMF@
MC)\B4$"1K#BQCN&9N4_*<6GG1M%WNA[/,!;/`WRWO`\QF.4N'$BO`UYC`CEC
M5#)-VY>2$2^X<P>"E.(CN'D.7'?8"!_AL&^M!^H6_KC<<CK2W<XP`FKJG$=@
M[1[5E/3M(9;"M!56D](&SPF*G;YPB8C=_.//M%3>/N`;.'2*QP#_`(04'P/H
M.O4O]NW2;RRZ.W6H2L+;*ZU%_E.J/B\M\C']_P`+L,?95:S];)H7;I9!&:RQ
MP-S#LS!I'T(QG#ELT24<.W"#5!(AE55G"J:*229"B8ZBBBABD(0A0W$1$``-
M;_K#:YE^R78*C?(_\BF'.GM7N<.^Z^XLEG]DOCUK()?B,ES,.]CD9>&C9!)R
M9F^%FD4"QKE`QRJ?<*B`&TK[TPX+IE9-FS)FU9,R$3:LVZ+5NFF!0(FB@F5-
M,A0+L4`*0H!XT1#=W$P=`]B^N64L4S?V)%INKR;JNO)!1%)M%VV,:+O:Q*K*
M+B4J:+"9124./(OT%'Z@T1<@'Q.]WX[J%VGDJ+DNPHL,67N1DJ!:Y-=14T5!
M3\;(.6,59"`*@-VR3N89-T'#DPB1)F8QA'B7?2J@XT*[A8:=A+'&LYBOS$7.
M1$@W3=L)2(?M9*/>M52@9)PU>,U5F[A!0H[@8AA*(:*JI[YM+?`5_H5DUD^F
MXME*3;NNL86.<2#=![*O$YV/=JMF#45`<.U4VC910Q2%,($((CX`=$Y*L#_\
MZN2*L%E["5*3L42PLLTE59:$A'D@BWD)6/C$7+61=,&KA0BCI-FX?)%.)`'B
M)PWT4&*O"^0#I'4>[.&G=86.TA\DUM)Y)8TNAB"8\3+'1_EC'QDBF57@991)
M/[E(O$QCI)B!@XCN57+1T6[\95^-3/ECP=G>+FFV-O[H&"R52G1E5W=+F$'@
MMG%LKI-U6Z_M(G4,N1`>#X")AS#@`Z5"E:8%=E459<.]E<7/BP-BJ^2<:Y#K
MKR)D#0DRRE(^3AIID9L_CUU8]RJ**AVS@Q%";@<@CHKP7(-V'ZR]F/B2[)U_
ML3CF-?7;$$/9#/*W<V"3I5L:$DU"HS-'O:+-)<U<6DF:RC,BX@=`Z*Q/;.94
M#D*4X8\5T]=-._W7SNI2&$[CFW1K"Z(M2%M6,YMZS87&OR"229G@DBE7`N).
M'YGW1>-P41,0=C"50IR%*X<D;_\`C^FB(/\`MSWAP%TTH;^W96N$:6:%N<*Y
M0HQZU=W&SOC$.*"#"&(L+I)ER)NJZ4*5%(H>HF$I32J>*&SXJ^PF8.UV,<J]
MD<GSJW]K9!R9+,,7TLZ;)*.H%:JC^9CUHEDZ1;-G#]1<J[<%W"PF%4Z'(O'<
M0U4Y((?E^[FQ-]M./?C^P[>85.S90MT9%99L",HC^'K\6Y,1%I59>005.T]J
M6^X7%ZF)@.W.U(4X`([:F"&G#M5\F&\9U3#>+Z1B^DHD0K5)KT=!19"G34.9
MNS0*F"RRJ?\`SEE1`1,<=Q-^XZJ)SW2JP%ZJ5EI5I;$>UNVP4K7)UDH<I"NX
MF89+,)!N)C`8`!9JN8N^P[;Z(N$K'^89/XT?D=FF;F81D*[C?(Z]4NAXLQG[
M)Y0[.BU</E$4&IU4GSN#KL^8R)`$1!REMX-Z2OO4X&G)=S>-,IX^S#3X.^8V
MMD';JO86#>0CI.$DV4BD*:Z8'%NX%HNL#=XV/NFLD80.DH4Q3``@.JJI`T10
MQF?!U0S9!HQEA!=C)QXJJ0L^Q`OWT8JL!04*!3_0NV6%,@G3-MRXAL(:P?UN
MZ";,ZYZ''IVXP^#5;;,;:[BIYL)?3,*'!\;BUN9AI7**.&-?L=G;VU;9EZZX
ML*/MI*"2)WRO`X<,0X5-#W\"JXK#T#R^R>+%KMEI\W'<S`@X=N9*(?F(;8.2
M[,S-ZW3,(>H%74WVUYRZY^WOU2L+YXV_J&D7NG!WX;GOE@E(K@71^4]C:?RR
MNYK8.PZ[;4FB!U"VNX;BF(:&2-KW.S-)]K0M2CT>["H>".Z8`?H`3SP`#_#_
M`--'QKC6_H@]0-K3R)]*`'_*=_E+DR=9]@R?,R[_`,)OWUZS=*NQAP*4[ZG&
M`@<2@,^['B7<3;%`8SP'(1';]]<^3T9^HZ1@8^ZTHM:*"MTXT'&@_"X5Q7\A
MU@Z>@U$=W4_U3?OKP*]&>P*HB)G%,-O^@S[S]0V'P$:`>==-<^A7KW=C]5-I
M3QQH;I]/=Y2Y#.M6PV?*V[']TW[ZE/'?Q_3XR#5YD^W1J4:B8BRT/4Q=.'3K
MCL)6RDG(-FR34@AX4$B*H\=P*(;@8,B[!_;PU>748KGJ7JUM'I+2'/@L<SY)
M1Q\LS2QQMB!/SN:R0TJ&D$AX^:U[KS8BW=%MNTD-R<!)/E#6_P`P8TN+NZKF
M]I[%9G7X"'J\/'P,"Q0C8J,;(M6;1`O$I$D4RIE$YO)U5C@7<YS")SFW$1$1
MUZ>;;VUH>T-#MMN;<MH[31K2)L<<;!0!K0`"3Q<XTJY[B7/=5SB225KA?W]Y
MJEY)?W\CI+J5Q<YQYDFOL'8!@!@!10#V"ZB8&[1J5P<W5::MK:JIR",7%M+[
M?JM"*IR9VJCLLQ"5*S0<58.1F9.`OD7`I!R`G$#&`>\7#0M!\/GQNH.$TF_7
M:#CWYR**-E&%XR''2B8)\/<<,G#2X(/43I"<NZB9@$NX>0WT4H$=>(<.T7!=
M,;T''32;8UEH[7>H-Y^VVNZR!%W"3=%3>;N4S.S1T?;:D`J9G`IDV$2@`B.Y
M517G[IIU\[/2$;(YIJL_:313%.-08L<C9&JD*X8I.7#LK>4@JC:H*'F""LZ/
MR%T@L)BCQ$1*``!$-G_TX_&\/KUEKH^=_-GOH^?W\VG12@4T83^/SJIUTF9B
M<PU0)NDNIV&?0,BS9Y,R@^A#1TBW4;.BMJ]+7%_!L')DE1XKH-TUTS_44X&`
M!T5&"BF6^(WH#8I%],6C"#JV2DBY.Z<R%MRAENSNO=4$PG!NK.7E\9HB(F_Y
M:7`G^&BE*K7!\.GQRI[F;=<8M@OL'!Y&7;)$8_0$#`8#MGS"X-W;90!#P8AR
MCHE`CCP[AN@X$HK/'6-F<Q&U*-=OWS1K/VVU71\BM(K>^Z`9VYS,]-G;^Y_0
MD9P*:1?!"E#QHJAVSK\>72_M+>&>5,S88@+Y<T(E*%3LA)VS11WD6@8QVK=^
MG6YZ,8RH-!4-[)UTU3I`<W$0Y#N3BFG1_BRZ-8SL\#<L>X;=4NPUR492\:]K
M62<I1"8O&"Y'+8LBR9W1)C+LBJIAR;.TUFZA1$IB"4P@+B@`"/E_%QLK'N(F
M48,Y.,=MS-'<?(-D7K-TV4(*:B#ELY(JBNDHF(@8I@$!`?.B*NW)'Q*]"LD3
MQ[:?![*A6\51<H67$UALN,7K1Z)A/]\W95"5C(7[OW#"83G:GW,.X^=$H%]2
M^,_':4<G#!V/[M&A2)D0_#CVGR86-.V*8#"V%J21*F"!MMA`-O\`#;4HF"U4
M1\/?Q\Q\DI.3&#3WJP.517?3V1;]D2[R,@N.^ZKP)ZTNV9S&W\@"10'U$!'S
MJJ4")BT=..N=KQ!$8%7QZ2NXE@Y9*;CJ=C^Q6K&[-.020=MQ.LZH<W7I)X@X
M(^4%=%98Z*YQ`ZA3&*40*H:#?#K\<1U!6/UJ@3K&-S,L:V9`,L)Q'?F*HVL5
M!/O^N^^BE`BTP)U@PUUFC9F'PY`3=>C)Y9HL_92MYO-R0(9D#@&Q(XESL4_^
M)03!T</;:^R0VX;@.P;%5[,[]<,4=DZ_'U?+<78I>$C%W+ANTK]]O=#,H=X1
M!-P1ZZHMCKCN004(W*'M+G43#SL`<AW(@]-\.?QPG$3*]:H)90WDZR]MR"NN
MJ;;85%EEK8=590_J8QA$QA\B.BE`G]C+XR.EF&;G#7_%>*)*B66!5]]@M7<F
M9481AU-C@(R,`G=/P4L`E.("#ILL`AL`^`#148(^-$2T1+1$M$2T1+1$M$2T
M1-"_W*`QY2[-=K2^)&UZM1#N4E7JA_;(W:H)CR,)^1!*(F,``("`[CHBI+ZC
M]C\'8\E+?GO-5XF65AR58QAZ="NPL]S_`+`IZJRZK8).Q*$D2M6\Q[Q>*:[@
MSD0:C_&.PZ455XLW:*]6H%S9[!,,(:`9M/OG4K(KD;-$6PI^Z"ACJ"&XF3\@
M4`$QO0`$=%$'F!;+A3..8;QF;%65,FV9S#[5F7J\DYD(_'Z"GVHE*ZBH21BV
MKDVX.^11,H``H7F!`WY&*J>,C]@,88OFX6J6":<O[M9!_P#(*)5XQ]9[C*$`
M%1,Y1@HA%RZ;LDRH',9=?VD0`AAY>!TJHM_B[+M`S)`N;%C^=3F64?*/H.7;
MG0<,I*$FXQPJTD(B7CG::3IB_:N$3%,4Q=C`'(HF*(&$B%3LOW=A\.7*D8RQ
MU#M,KY&LDV"$W5Z\L[G92OP;9%PO(K*15;3D),TTFBA[B;4R93&3`QAV*`CH
MB(/"O8O%.?F]A-CJ<=.Y&H2(1%K@)B(DH"?KTES<$^TDHN4;H+)+`=JH!@*)
M_;,7B?B;QHE*<4$7R<Y#:,*YB_$\/83P-XR-;B(M7W]Q/(6.85MD1,LX>:^V
M>M6@)+F>M_:,Z`Q=BFX@.XZ(IYP'V2ZXIRE2ZVT&R2WYN"J30:ZE-UF?@6L_
M$LB$0![%OIIBR"0*X.8!3.`;+[_QB?8=B=Z,B2DXV&CWDM,2#**BX]NJ[?R4
MDZ08L&+5`HG6<NWCE1)NV;I$`1,<Y@*4`W$=$0R3/<[`43;JA1D;),SEEO,D
MVC:VS@ZG9'3:1!TZ*S3D6LJYCFD4^AP<B8IW3999(@IGY"'$=$4L96S-CC"=
M:/:LD6)&`C>*OVR((.7\K(JHHF76;QL5'I.7SY5%$HG4$A!(DF4QU#%(4Q@(
MAZ9_(/U:D#4DC&]2#P][D$8N+*UJMC<?CY!RNHV:M)XZ,<HE%.G*Q`X)&,*@
MI*%5X^R/N:(B"RSFO&>#ZXI:,EV=K7XTH#["7LN7\H_.`"/MQ\3'HN9!X8`*
M.XD3X%`!$P@`;Z(AVDOD/ZK1=;KMK6O3]Q#6)PQ:%=,*S./T89U(I'6;-+$\
M;,U(Z(>F33./L*+"N($.8""4AQ*2B>$5W5Z\3F2Z]BF%N+J4LEK6,UKKQG7Y
ML];F'93)E!O'6`S$D>^Y>Z`@JB8[?;R*@`(;D15**)HIG564(DDF4QU%%#%(
MFF0H;F.<YA`I2E`-Q$1V`-$0KWONCU\H(QB;ZVOYUQ.3"<!`IU*MS]@:3\N9
M5%%2/@YQHP"N2SMJ=PG[J2#PZB8*$W+]1=R(HF;I-\S:O4BJD2>-D'29%R"D
ML1-PD54A5DA\IJE*?8Q1]!\:(O3HB6B):(EHB6B):(EHB6B):(JGOE"G+K,1
MV'L+L8^V1N,<E6DRV4L@UBN3MD)68.',BA^/DF<"PDG:C:6))'/[8)'$XH`(
M!XT1:^.Z]M>P33&^)Z1C1_BKI_C:6C;3+O[7#!`77,=FC@*1F5*ONT22[2+(
MD147#Y^";A<5R[)AP$-%<`IO^1')$WCG`J4!2L>2M[N5QD$(*HG9561M#6FO
MFA6Z2=P53CF,@JSE($7A%V!O:,)UDQX^2Z*)Z=$<6AB?`\5`+4>9ILB[DG<M
M).;.JP"TVQX^1;*+6.?C8_W4()TJ?=NFT]Y<2H-R*"8#*"0JM5579AVQW/#E
ML[5Y5R?1+[:^U=JO$S0<7U>'I=AF1?0KB*BC52?B9P&"E?CX1N+L`=K?=)`!
M$52B/KHB.KHQ@FQ]:<+6ZP98>HM;QD.PSV6\C-4G'W+&O/'2:[E=J1P`\3G;
M1B)3N./TE6Y@`F`.0DPY(`<`YKJ5U[(=A.V\]`6>30C"/Z'@:KU:BV.;3MJK
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ML!EK$UCC'L*1[2*9'2L,\JM6Q57&;-QL>%&99F6GE9A1ZNB"38`%%3=03\#!
ML4XHA?D=C;QDJ-QK@#&5+FY.QY6LT8QLU\CZX\7:T.C,WIGTE('M!6IF,>J<
MK!4BC8ZZ1ETC\-C`H`"1&M@[!M'P/C2L8WJ<6S!G`,T@=R*C5#[V8ES\EG\N
M\5$@J'7<NE#B0!$?:3XD*/$H:(@&[RU2^=C\O4#K/0Z?*0\*^8?E,N9I7J[\
M&$32DEF\I_9<?8E&J;1\26?_`&JYT&S@52.D2"8H\#;$0\CUU3S7E`F*&%`N
M-!Z?=2VKM5TB]K,M"3F:KNT)L\>-A<-&:L\:5<LG"A9!`%`$B@@(?RAJ=ZM!
MPY)W=%(.UY@[!6OL-<L062O1,>@M4L8Q$_#*4NNXLID:Y]B'81<'),14F9A6
M/01*DJU(B5N#<_-3=0NJE01WJ6NXV5[C*=BL=8!EJ7EEW@Y:&2M%U<XVK$I*
M*Y+DW3E-"-QXZE6AFK9E$*I(+D?$4<MTCE<D]PP``"!10%B&6RUV![HQLU><
M$VBM8^P*]81F,\>+Q2T%2JG]TYY/+K)6%XR3CI&QPZ*"*R23%)3[PZ)4C&2X
M@<Q7PY*]H/\`;;_8-%$M$2T1+1$M$2T1+1$M$2T1+1%@?AM_)PX[A_7MMO\`
MI_5XWT\46>B+$W'QRX_U!QY;?U?IMO\`ZM$66B+`?:]P-^'N\?IWX^YQ\[[?
MZN._^[1$-'<4C%3K=E(LJXR4UAQ@B?FE\1,ZR_OY(8'K493\(UM[Z-@5""QY
M@Y]Y8@@U]P2[FV`2H3=Z+AA@O5[$Y<$J2RV.@AW`0RME1C&]E4?`\<?GC3B$
M2NZC4I@TO[WW16ZAT05Y<!$NPZ(:^Q%YHHL3<-OKX\?UY;;?]?C1%EHB^?3R
M'TY;!OZ<N.X[;_KMOOHB^$X;?1QX[C_1MMO^OIXWT19:(EHB6B):(L2\>(<.
M/']..W'_`';>/71$AX\@WX\MAVWVY;>-]OUVT1?0X_5QX_U?5MM_5L&_+;_5
,MMHB^Z(EHB6B+__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
